ARTMS gets funds to develop Zr-89 for PET

By staff writers

March 3, 2021 -- Canadian radioisotope developer ARTMS has received $300,000 Canadian ($237,590 U.S.) from Innovate BC to help develop the radioisotope zirconium-89 (Zr-89) for PET for patients who are eligible for immuno-oncology therapies.

This money, along with $600,000 Canadian ($475,000 U.S.) received from other resources, will be used to produce Zr-89 for the radiolabeling of molecular targeting ligands, such as antibodies, that are used in the noninvasive monitoring of the immune system by immuno-PET.

Copyright © 2021

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking